Product
Disitamab vedotin
Aliases
disitamab vedotin, RC48, RC48-ADC
3 clinical trials
10 indications
Indication
cancerIndication
Squamous Cell Carcinoma of Head and NeckIndication
Non-Small Cell LungIndication
Ovarian CancerIndication
Endometrial NeoplasmsIndication
Breast NeoplasmsIndication
Esophageal CancerIndication
HER2 Low Breast NeoplasmsIndication
Stomach NeoplasmsIndication
Solid TumorClinical trial
A Phase 2 Basket Study of Disitamab Vedotin in Adult Subjects With Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors That Express HER2Status: Recruiting, Estimated PCD: 2026-05-31
Clinical trial
A Phase 1b/2 Open-Label Study of Disitamab Vedotin Monotherapy or in Combination With Other Anticancer Therapies in Solid TumorsStatus: Recruiting, Estimated PCD: 2030-01-31